» Articles » PMID: 12023346

Valpha24-JalphaQ-independent, CD1d-restricted Recognition of Alpha-galactosylceramide by Human CD4(+) and CD8alphabeta(+) T Lymphocytes

Overview
Journal J Immunol
Date 2002 May 23
PMID 12023346
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Human CD1d molecules present an unknown ligand, mimicked by the synthetic glycosphingolipid alpha-galactosylceramide (alphaGC), to a highly conserved NKT cell subset expressing an invariant TCR Valpha24-JalphaQ paired with Vbeta11 chain (Valpha24(+)Vbeta11(+) invariant NK T cell (NKT(inv))). The developmental pathway of Valpha24(+)Vbeta11(+)NKT(inv) is still unclear, but recent studies in mice were consistent with a TCR instructive, rather than a stochastic, model of differentiation. Using CD1d-alphaGC-tetramers, we demonstrate that in humans, TCR variable domains other than Valpha24 and Vbeta11 can mediate specific recognition of CD1d-alphaGC. In contrast to Valpha24(+)Vbeta11(+)NKT(inv) cells, Valpha24(-)/CD1d-alphaGC-specific T cells express either CD8alphabeta or CD4 molecules, but they are never CD4 CD8 double negative. We show that CD8alphabeta(+)Valpha24(-)/CD1d-alphaGC-specific T cells exhibit CD8-dependent specific cytotoxicity and have lower affinity TCRs than Valpha24(+)/CD1d-alphaGC-specific T cells. In conclusion, our results demonstrate that, contrary to the currently held view, recognition of CD1d-alphaGC complex in humans is not uniformly restricted to the Valpha24-JalphaQ/Vbeta11 NKT cell subset, but can be mediated by a diverse range of Valpha and Vbeta domains. The existence of a diverse repertoire of CD1d-alphaGC-specific T cells in humans strongly supports their Ag-driven selection.

Citing Articles

Immune Profile in COVID-19: Unveiling T Cells in SARS-CoV-2 Infection.

Carriero F, Rubino V, Gelzo M, Scalia G, Raia M, Ciccozzi M Int J Mol Sci. 2024; 25(19).

PMID: 39408792 PMC: 11477006. DOI: 10.3390/ijms251910465.


Thymic development of human natural killer T cells: recent advances and implications for immunotherapy.

Pellicci D, Tavakolinia N, Perriman L, Berzins S, Menne C Front Immunol. 2024; 15:1441634.

PMID: 39267746 PMC: 11390520. DOI: 10.3389/fimmu.2024.1441634.


CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy.

Huang J, Yang Q, Wang W, Huang J Front Immunol. 2024; 15:1378739.

PMID: 38665921 PMC: 11044028. DOI: 10.3389/fimmu.2024.1378739.


Regulatory T Cells in the Complex Panorama of Immune Activation and Regulation.

Carriero F, Rubino V, Leone S, Montanaro R, Brancaleone V, Ruggiero G Cells. 2023; 12(24).

PMID: 38132162 PMC: 10742044. DOI: 10.3390/cells12242841.


Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.

Zappa E, Vitali A, Anders K, Molenaar J, Wienke J, Kunkele A Eur J Cancer. 2023; 194:113347.

PMID: 37832507 PMC: 10695178. DOI: 10.1016/j.ejca.2023.113347.